Results 221 to 230 of about 29,845 (261)

Praziquantel Therapy for Cysticercosis

Archives of Neurology, 1983
To the Editor. —Both in their editorial entitled "Cysticercosis: An Old Scourge Revisited" (Archives1982; 39:533) and in their article entitled "CNS Cysticercosis" (Archives1982;39:540-544), Grisolia and Wiederholt commented that no specific medical therapy is available for neurocysticercosis. The accompanying article by McCormick et al (Archives1982;
Susan Mates, Joseph H. Friedman
openaire   +3 more sources

Treatment of Cysticercosis With Praziquantel

Archives of Neurology, 1984
To the Editor. —Two recent reports 1,2 have cast some doubts on the efficacy of praziquantel in the treatment of neurocysticercosis. Because this disease is an important neurosurgical problem in Latin America, we wish to report briefly on our experience with this drug.
Jaime G. Gomez, Eric Sanchez, Rodrigo Pardo   +2 more
openaire   +3 more sources

Praziquantel and Refugee Health

JAMA: The Journal of the American Medical Association, 1984
PRAZIQUANTEL is a new drug that is effective against a broad range of parasitic fluke (Trematoda) and tapeworm (Cestoda) infections. In June 1983, it was approved by the Food and Drug Administration for marketing in the United States. The compound was developed and introduced in the mid-1970s through a joint effort of Bayer AG and E.
Peter M. Schantz, Bruce G. Weniger
openaire   +3 more sources

Praziquantel: The enigmatic antiparasitic

Parasitology Today, 1992
Praziquantel (PZQ), a pyrazinoisoquinoline, was introduced as a novel anthelmintic in 1975. PZQ is currently the drug of choice for the treatment of a wide range of both veterinary and human trematode and cestode infections, including human schistosomiasis.
Tim A. Day, James L. Bennett, Ralph A. Pax   +2 more
openaire   +3 more sources

In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel

International Journal for Parasitology, 2001
The resistance status of five praziquantel-susceptible and five praziquantel-resistant isolates was confirmed by chemotherapy in CD(1) mice with 3 x 200mg/kg micronised praziquantel. Micronised praziquantel had higher efficacy than two other praziquantel formulations (prepared without milling).
Michael J. Doenhoff, Y.-S. Liang, Gerald C. Coles, Vaughan R. Southgate   +3 more
openaire   +2 more sources

Praziquantel in the Treatment of Cysticercosis

JAMA: The Journal of the American Medical Association, 1986
To the Editor.— The recent article on cysticercosis in Los Angeles County documents 497 patients followed up over an 11-year period and underscores the need for heightened physician awareness of this seemingly rare disease. 1 While the authors note that anticonvulsant therapy may be used to control neurocysticercosis and mention the role of surgical ...
Jay A. Levin, J. Graham Smith
openaire   +3 more sources

The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel

European Journal of Clinical Pharmacology, 2019
The study sought to determine the effect of ketoconazole (KTZ) on the pharmacokinetics of praziquantel (PZQ) and on the formation of its major hydroxylated metabolites, cis- and trans-4-OH-PZQ, and X-OH-PZQ in healthy subjects.Two treatments were evaluated by single-dose PK studies; the reference treatment was a 20 mg/kg dose of praziquantel given ...
Lovejoy Nleya, Roslyn Thelingwani, Xue-Qing Li, Erika Cavallin, Emre Isin, Charles Nhachi, Collen Masimirembwa   +6 more
openaire   +3 more sources

Schistosome resistance to praziquantel

Drug Resistance Updates, 1998
Praziquantel (PZQ) is the drug of choice for the treatment of human schistosomiasis. In 1994, it was first demonstrated that by sustained drug pressure on a Schistosoma mansoni strain in laboratory conditions resistance to PZQ can develop. Studies in Senegal and Egypt, both schistosomiasis endemic areas, have found that there are schistosome strain(s ...
openaire   +3 more sources

Determination of praziquantel and of praziquantel in tablets by gas–liquid chromatography

The Analyst, 1992
Praziquantel was determined by gas–liquid chromatography (GLC). The determination was based on the concept of internal standardization; papaverine was used as the internal standard. Five independent analyses of two samples containing 0.105 and 1.370 mg cm–3 of praziquantel showed relative standard deviations of 0.540 and 0.155% respectively.
J. Schnekenburger, H. Saleh
openaire   +2 more sources

The anthelmintic action of praziquantel

Parasitology Today, 1988
Although fairly expensive (around US$4.00 per single dose) praziquantel is now the most favoured drug against all forms of schistosomiasis, and against many other helminth infections. It is now marketed by four companies: E. Merck and Bayer (F.R.G.), Ames-Myers (USA), and Shin-Poon Pharmaceuticals (S. Korea).
openaire   +3 more sources